

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 March 2012 (29.03.2012)

(10) International Publication Number
WO 2012/038824 A1

(51) International Patent Classification:
A61B 6/00 (2006.01) *A61B 6/03* (2006.01)
A61B 5/00 (2006.01)

(21) International Application Number:
PCT/IB2011/002381

(22) International Filing Date:
20 September 2011 (20.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12/933,477 20 September 2010 (20.09.2010) US

(71) Applicant (for all designated States except US): **NOVADAQ TECHNOLOGIES INC.** [CA/CA]; 2585 Sky-mark Avenue, Suite 306, Mississauga, ON L4W 4L5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DVORSKY, Peter** [CA/CA]; 33 Joseph Duggan Road, Toronto, ON M4L 3X5 (CA). **GOYETTE, David, Mark, Henri** [CA/CA]; 5218 Charnwood Cres, Mississauga, ON L5M 2J9 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: LOCATING AND ANALYZING PERFORATOR FLAPS FOR PLASTIC AND RECONSTRUCTIVE SURGERY




FIG. 1

(57) Abstract: A method and an apparatus for preoperative identification of a perforator vessel for plastic and/or reconstructive surgery using ICG fluorescence angiography imaging are disclosed. Time-resolved image processing is used to highlight perforator locations and to enable visual discrimination among candidate perforators by various computed metrics. Based on these metrics, the surgeon is able to interactively locate and select perforator vessels suitable for plastic and reconstructive surgery.

WO 2012/038824 A1

LOCATING AND ANALYZING PERFORATOR FLAPS FOR PLASTIC AND RECONSTRUCTIVE SURGERY

BACKGROUND OF THE INVENTION

5 **[0001]** Plastic and reconstructive surgery often entails the localization and clinical evaluation of a flap of skin and subcutaneous tissue which is supplied by isolated perforator vessels and that is potentially suitable for grafting in another part of the body. Perforators pass from their source vessel to the skin surface, either through or between deep muscular tissues. Well-vascularised flaps are good candidates for grafts.

10 **[0002]** For example, abdominal donor-site flaps have become the standard for autologous breast reconstruction since the early 1980s. Within the abdomen, free fat options range from complete transverse rectus abdominis musculocutaneous (TRAM) flaps to isolated perforator flaps, such as the deep inferior epigastric artery (DIEA) perforator flap. Perforator flaps have allowed the transfer of the patient's own skin and fat in a reliable manner also in other areas of tissue reconstruction, with minimal donor-site morbidity. Flaps that relied on a random pattern blood supply were soon supplanted by pedicled, axial patterned flaps that could reliably transfer great amounts of tissue. The advent of free tissue transfer allowed an even greater range of possibilities to appropriately match donor and recipient sites. The increased use of perforator flaps has escalated the need for a pre-operative familiarity of an individual's particular anatomical feature of the DIEA and its perforating branches, particularly given the significant variation in that anatomy of the vascular supply to the abdominal wall.

20 **[0003]** Localization and evaluation of perforators is a painstaking and time-consuming process. Pre-operative computed tomography angiographic (CTA) imaging is often performed to do the localization. Such an approach entails considerable expense and has the additional complication that the surgeon must mentally correlate the images from the previously acquired 3D modality with the current 2D view of the patient now lying on the operating table. The search for a more favorable imaging modality is thus continuing, with recent interest in the use of indocyanine green

(ICG) fluorescence imaging, wherein blood circulation is assessed through the skin on the basis of a fluorescence signal.

5 Fluorescence in ICG with an emission peak around 830 nm occurs as a result of excitation by radiation in the near-infrared spectral range. Excitation light with a wavelength around 800 nm can be produced, for example, by a diode laser, light emitting diodes (LED), or other conventional illumination sources, such as arc lamps, halogen lamps with a suitable bandpass filter. The skin is transparent to this wavelength.

10 **[0004]** ICG strongly binds to blood proteins and has previously been used for cardiac output measurement, hepatic function evaluation, and ophthalmic angiography, with few adverse reactions. Evaluation of ICG fluorescence signals can be used to locate perforators. Since the skin surface near a perforator
15 generally accumulates more blood and at a faster rate than the surrounding tissue, once ICG is injected, perforators tend to fluoresce brighter and faster than the surrounding tissue. This rapid, high-intensity fluorescence enables visual localization of the perforator. Often, however, the surgeon is interested not merely in localization but also in evaluation and comparison to support good clinical decision making. The surgeon needs to decide which of
20 several perforators the best graft candidates are. Here, simple visual observation while fluorescence rapidly accumulates and dissipates does not suffice. For example,, the tendency of residual ICG from successive injections to accumulate in tissue and to gradually raise the background brightness with each injection further confounds easy visual discrimination of the best candidate perforators. In addition, ICG sometimes moves exceedingly slowly over several minutes making such on-the-fly analysis very
25 challenging and subjective. A surgeon will make an assessment by raising the following questions:

- 1) How much ICG-bound blood is in the tissue?
- 2) How long does it stay in the tissue?
- 3) How quickly does it move through the tissue?
- 35 4) After the bolus is injected, in which order do anatomical areas light up?

[0005] These questions are difficult to answer on a subjective basis. Accordingly, there is a need for more advanced image processing and display methods to apply objective standards to localize and evaluate perforators.

5

SUMMARY OF THE INVENTION

[0006] According to one aspect of the invention, a method for preoperative identification of a perforator vessel for plastic and/or reconstructive surgery using ICG fluorescence angiography imaging is disclosed, which includes time-resolved image processing to highlight perforator locations and to enable visual discrimination among candidate perforators by various computed metrics. The surgeon is able to select and compare the results of algorithms that analyze the time series and output the metrics according to at least one of the following processing acts:

10
15 Determine time-integrated fluorescence on a pixel-by-pixel basis. Compute an average fluorescence by dividing the time-integrated fluorescence by the elapsed time.
Determine a rate of increase/wash-out in the fluorescence.
Determine the elapsed time to achieve peak fluorescence.

20 **[0007]** The various image processing steps process the image pixels independently and compute a unique numerical metric for each pixel in the input sequence observed across the entire time of the acquisition or a selected temporal sub-range. Each image output is thus a numerical array having the same dimensions, i.e. number and arrangement of pixels, as a frame in the input image sequence. Thus, the processed image can be displayed, for example, as a three-dimensional representation, for example a contour map, of the computed pixel values across the imaged area, or as a color-coded two-dimensional image or a relief map. Such image representations facilitate rapid comprehension of image features and comparison between regions on the images, in this case the location of the perforators under the skin.

25
30
35 **[0008]** These and other features and advantages of the present invention will become more readily appreciated from the detailed description of the invention that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0009] The following Figures depict certain illustrative embodiments of the invention in which like reference numerals refer to like elements. These depicted embodiments are to be understood as illustrative of the invention and not as limiting in any way.

5

FIG. 1 shows schematically a camera system for observing ICG fluorescence;

10

FIG. 2 shows an ICG fluorescence image of an area of skin, with the pixel values integrated over time;

FIG. 3 shows an ICG fluorescence image of an area of skin integrated over time, with the pixel values inversely weighted by elapsed time;

15

FIG. 4 shows an ICG fluorescence image of an area of skin, with the pixel values determined by the rate of increase of fluorescence;

FIG. 5 shows an ICG fluorescence image of an area of skin, with the pixel values determined by elapsed time to maximum fluorescence; and

20

FIG. 6 shows an ICG fluorescence image of an area of skin, with the pixel values determined by peak fluorescence;

FIG. 7 shows an overlay of the fluorescence image processed with a variable contrast transfer function;

FIG. 8 shows an overlay of the fluorescence image processed with another variable contrast transfer function;

25

FIG. 9 shows an overlay of the fluorescence image processed with yet another variable contrast transfer function;

FIG. 10A is a fluorescence image of the perfused region; and

30

FIG. 10B is a black/white rendition of a colored overlay corresponding to the fluorescence image of FIG. 10A, with markers indicating a normalized intensity.

DETAILED DESCRIPTION

[0010] The invention is directed to preoperative determination of the location of perforator vessels in perforator flaps by a non-invasive method, before any incision is made.

5 **[0011]** FIG. 1 shows schematically a device for a non-invasive, through the skin determination of tissue perfusion in operative, in particular preoperative, applications by ICG fluorescence imaging. An infrared light source, for example, one or more diode lasers or LEDs, with a peak emission of about 780–800 nm for exciting
10 fluorescence in ICG is located inside housing 1. The fluorescence signal is detected by a CCD camera 2 having adequate near-IR sensitivity; such cameras are commercially available from several vendors (Hitachi, Hamamatsu, etc.). The CCD camera 2 may have a viewfinder 8, but the image may also be viewed during the
15 operation on an external monitor which may be part of an electronic image processing and evaluation system 11.

[0012] A light beam 3, which may be a divergent or a scanned beam, emerges from the housing 1 to illuminate an area of interest 4, i.e. the area where a flap with suitable perforator vessels is
20 expected to be located. The area of interest may be about 10 cm x 10 cm, but may vary based on surgical requirements and the available illumination intensity and camera sensitivity.

[0013] A filter 6 is typically placed in front of the camera lens 7 to block excitation light from reaching the camera sensor, while
25 allowing fluorescence light to pass through. The filter 6 may be an NIR long-wave pass filter (cut filter), which is only transparent to wavelengths greater than about 815 nm, or preferably a bandpass filter transmitting at peak wavelengths of between 830 and 845 nm and having a full width at half maximum (FWHM) transmission
30 window of between about 10 nm and 25 nm, i.e. outside the excitation wavelength band. The camera 2 may also be designed to acquire a color image of the area of interest to allow real-time correlation between the fluorescence image and the color image.

[0014] In the context of the present invention, the device illustrated
35 in FIG. 1 is used to identify/ locate perforator vessels prior to surgery— this will assist the surgeon in selecting the best flap or flap zone for use during the reconstruction.

[0015] In other post-operative applications, the device can be used to:

5 Validate anastomotic patency and arterial and venous flow – this can potentially improve outcomes to eliminate flap failure which can be a result of poor arterial flow and inadequate perfusion as well as poor venous return resulting in congestion.

Visualize and confirm complete tissue perfusion, as micro-vascular perfusion to the entire flap and native tissue is critical to flap survival.

10 **[0016]** With the invention, perforator locations are visualized by image processing and presentation techniques to enable easy and objective visual discrimination among candidate perforators. ICG is injected and the entire ICG fluorescence perfusion and wash-out cycle is captured by the imaging device. After image acquisition,
15 the entire sequence or some temporal sub-range of the images is processed by an image processing algorithm, which may be selected by the surgeon.

[0017] Processed results of the fluorescence measurements may be visualized, for example, as false color images or as a contour map, to enable rapid visual evaluation according to the applied
20 algorithm metric. For example, the fluorescence intensity for each pixel may be rendered as a spectral color varying from blue (“cool” spots or low fluorescence-intensity or rate) to red (“hot” spots or high fluorescence- intensity or rate). Other spectral associations are easily accommodated. The output may be presented as a semi-
25 transparent overlay on the original anatomical images. This enables visual correlation of “hot” spots with the underlying anatomy. The meaning of “hot” spots varies with the algorithm employed, such as integrated intensity, weighted or unweighted, rate of increase or
30 wash-out.

[0018] The user is given interactive control over the “hot” to “cool” color mapping and can vary it in real time to explore finer or coarser sub-ranges of the dynamic range of each algorithm’s output metric. As the color window is widened, the hottest regions are highlighted
35 first, followed by the cooler regions. This kind of adjustment can be made by changing the mapping of luminosity or contrast between the acquired pixels and the pixels in the displayed image. Such

mapping functions may be included in standard imaging programs. This windowing process based on the currently employed metric aids in discriminating between perforators and enhances perception and improves understanding by the surgeon of the applied ICG dynamics.

5

[0019] The invention also supports the simultaneous display and evaluation of two sequences from two different locations on the patient's skin. This enables comparison of candidate flaps that are separated by a distance greater than the imaging system's field of view.

10

[0020] FIG. 2 shows an image of an area of a patient's skin where suitable perforator vessels are to be identified. Each pixel represents the time integral of fluorescence intensity over the exposure time for the image sequence. This mode is typically referred to as "integration mode" in image processing and many image processors offer this mode as a standard feature. In practice, the pixel intensities (collected charges in a CCD) acquired during each frame in the image sequence are added on a pixel-by-pixel basis, for example in the image processor, and divided by the number of frames, whereafter the sum may be normalized to a fixed dynamic range, for example, from 1 to 255 (8-bits). The notion is that brighter pixels in an image represent an area of the skin infused with a greater volume of blood carrying ICG over a preset period of time. In FIG. 2, the perforator vessel 24 exhibits the highest integrated fluorescence intensity, with another perforator vessel exhibiting weaker fluorescence intensity shown as 26.

15

20

25

[0021] Note that the transparency of the image has been set such that the physician's marker 22 is visible through the transparent color overlay of the ICG fluorescence image at the upper right of the screen.

30

[0022] FIG. 3 shows an ICG fluorescence image of the same area of skin integrated over time, with the pixel values inversely weighted by elapsed time. This image processing algorithm is similar to the previously described integration, but instead of adding the measured intensities of each pixel directly, the measured intensity values are first divided by the elapsed time after start of the observation of ICG fluorescence, before being added. In this way, earlier fluorescence signals are given a greater significance

35

that fluorescence signals acquired later. The “hottest” pixels are those pixels that in the sequence of image frames fluoresce earlier than other pixels which the ICG bolus reaches at a later time. The same perforator vessel 34 is identified as in FIG. 2, with another vessel 36 barely identifiable.

5
10
15
20

[0023] FIG. 4 shows an ICG fluorescence image, again of the same area of skin, with the pixel values in this image determined by the rate of increase of fluorescence intensity. In this image processing algorithm, a slope of the pixel intensity versus elapsed time is computed for each pixel in an image. For example, each pixel may have an assigned lowest intensity value (baseline) and an assigned highest intensity value (or another relatively high-intensity value). For each pixel, the time when the pixel intensity crosses the baseline and the time when the pixel intensity crosses the high-intensity value are noted. From this information, the image processing algorithm computes a rate of increase for each pixel in the image, with “hotter” pixels having a greater slope, i.e., they reach the high-intensity value faster than “cooler” pixels. This embodiment of the image processing algorithm thus highlights the speed at which the ICG bolus reaches the perforator vessels. The transparency has been turned off in FIG. 4, so that the surgeon’s tool is not visible in the image.

25

[0024] The previously identified perforator vessel, shown here with the reference symbol 44, is much better defined, as are the vessel 46 (previously shown as 26 and 36) and another vessel 48.

30
35

[0025] FIG. 5 shows an ICG fluorescence image of the same area of skin, with the pixel values determined by elapsed time to maximum fluorescence. Unlike FIG. 4, which displays the time rate of change, the image processing algorithm of FIG. 5 displays the time at which pixels reach their maximum intensity, with the “hotter” pixels reaching their respective peak fluorescence intensity sooner than cooler pixels. The algorithm thus highlights areas of the image in the order in which perforators reach their peak intensity. In this image, the previously identified perforator vessels 24, 34, 44 is again clearly distinguishable, as are the vessels 56 and 58 which correspond to the vessels 46 and 48 of FIG. 4.

[0026] FIG. 6 shows an ICG fluorescence image of the same area of skin, with the pixel values determined by the peak fluorescence

value at each pixel. Higher (“hot”) fluorescence intensity values 64 may indicate a higher ICG concentration or may be caused by perforator vessels located closer to the skin surface, which reduces absorption of the excitation light /fluorescence response. The
5 vessels 66, 68 which were clearly visible in FIGS. 4 and 5, are barely distinguishable from the background.

[0027] While the images shown, for example, in FIGS. 2 and 6 are rendered with a linear contrast transfer function providing a 1:1 mapping of pixel values processed with the various algorithms described above to the displayed pixel intensities, images can also be rendered (as contour maps or false color overlays) with a variable contrast transfer function to enhance the visual differences in the image. In addition, labels may be placed in the overlay images, hereinafter referred to as ACR (accumulated or time-integrated intensity ratio) labels, which facilitate a quantitative
10 comparison between two or more regions of the anatomy.
15

[0028] Because absolute pixel values in the image change when the dynamic range and slope of the variable contrast transfer function is modified, the ACR labels allow the user to compare the relative perfusion in different image regions as measured by any of the selected overlay techniques (e.g. accumulated/ time-averaged intensity, etc.).
20

[0029] The following approach is used to compute the ACR label values. For clarity, we assume that accumulated intensity is selected as overlay technique, although the same approach can be used with any of the available overlay techniques.
25

- 1) The accumulated intensity for all pixels for all images in the image sequence is computed over a time window.
- 2) The accumulated intensity is averaged over a region of the selected label (for example, a 5x5 pixel square matrix).
30
- 3) The averaged intensity is normalized to the maximum value of the accumulated intensity in the entire image.
- 4) The normalized averaged is intensity scaled, with the maximum value of the transfer function representing 100%.

5
10
15

[0030] By following this approach, the relative ratio of two different ACR labels remains unchanged even though the slope of the transfer function is modified. FIGS. 7 and 8 show a fluorescence image from the image sequence that has been processed with one of the aforementioned algorithms (upper part of the gray-scale image) and the false-color overlay image rendering the accumulated intensity from the sequence in color (from blue for low values to red for high values) for two different contrast functions. The pixel values in FIG. 7 are processed with a first contrast transfer function, giving two regions with 52% and 72% intensity, respectively, corresponding to a ratio of $52/72 = .72$ between the two labeled regions. The second overlay image in FIG. 8 shows the same pixel values processed with a different contrast transfer function, with the intensity in the two regions now labeled 99% and 71%, respectively. However, their relative ratio remains essentially unchanged at $71/99 = 0.72$.

20

[0031] The user can modify the transfer function so that a control region is labeled at 100%, wherein all other regions could then be compared to the control region.

25

[0032] FIG. 9 shows that the overlay is transparent where accumulated intensity pixels have a value less than the point where the bottom of the transfer function ramp intersects the horizontal pixel value axis. Further, this demonstrates that in this example 12% of the image area (Coverage number in the lower right of the bottom window) has accumulated intensity greater than 52% of the maximum accumulated intensity. The illustration shows several regions bounded by their 52% contours.

30
35

[0033] In the aforescribed approach, the user could place labels on the image to compare relative perfusion of different tissue zones. These labels would normalize the accumulated intensity in a small region beneath the label to the accumulated intensity present in the zone at the top end of the color map range of interest. Although the value of individual labels would vary as the color mapping range was shifted, the ratios of the labels to one another would remain constant.

[0034] Practical trials have demonstrated that modifications in the aforescribed methods would be desirable in order to better

quantify the results and allow a more consistent comparison between perfused areas.

- 5 • Clinicians generally want to perform a consistent comparison of the perfusion of suspect tissue to that of well-perfused, “good” tissue. One way of doing that with the original technique described above is to go through the burdensome process of manually adjusting the color mapping range until a label placed on well-perfused tissue reaches 100%. This label may now be used as a “good” tissue reference.
- 10 • Clinicians generally want to identify whether tissue which exhibits relative accumulated intensity at some percentage as compared to good tissue will suffer from necrosis. Inherent noise in the camera, variable conditions of illumination and surface reflectivity, and the presence of residual ICG in the
- 15 patient make it difficult to ensure that the ratios are consistent.
- Although the label ratios remained constant as the color mapping changed, clinicians found it confusing that the label values themselves vary in the process.

20 **[0035]** In one modified approach, two reference labels are placed on the image, either explicitly in a manual operation or implicitly through automatic computation as described below. The labels are denoted as the background or “0 Marker” and the reference or “100 Marker”. Any additional labels placed on the accumulated intensity matrix are normalized to the range established by these

25 markers.

30 **[0036]** Ideally, the “0 Marker” will be placed on native tissue outside the transplant flap. The accumulated intensity in a small region beneath this marker denotes background intensity that would result from background noise in the camera, possibly combined with signal from some residual ICG in the patient from prior acquisitions.

[0037] Using clinical judgment, the operator places the “100 Marker” on tissue that the clinician has identified as being well-perfused, “good” tissue. This establishes the “good” tissue reference.

35 **[0038]** The two markers now support direct normalized quantitative comparison of regions of perfusion on the flap.

[0039] Labels values are computed using the following formula:

$$L = 100 * (A_{\text{label}} - A_0) / (A_{100} - A_0),$$

where:

- 5 • A_{label} represents the accumulated intensity in the area beneath the label
- A_0 represents the background accumulated intensity in the area beneath the “0 Marker”
- A_{100} represents the reference accumulated intensity in the area beneath the “100 Marker”

10 **[0040]** All existing and newly placed label values are now normalized to the range between the “0 Marker” and “100 Marker”. Label values can exceed 100% and now do not change as the color mapping range is shifted for enhanced visualization.

15 **[0041]** FIGS. 10A and 10B illustrate an exemplary embodiment of this technique. FIG. 10A is a fluorescence image of the perfused region, similar to those described above with reference to FIGS. 2 to 6. FIG. 10B is a black/white rendition of a colored overlay, with markers or label values computed with the formula:

$$L = 100 * (A_{\text{label}} - A_0) / (A_{100} - A_0).$$

20 **[0042]** The “0 Marker” is denoted in the upper left corner by the circle enclosing a “0” and the “100 Marker” is denoted in the upper right corner by the circle enclosing a “100”. Because all areas of the tissue show some perfusion, the “0 Marker” has been placed on a surgical clip within the field of view.

25 **[0043]** The following are additional/alternative options for deriving values for the “0 Marker” or accumulated background intensity:

- 30 • If no separate “0 Marker” is explicitly placed, a value for the “0 Marker” can be derived by averaging the accumulated intensity present in the first frame captured prior to the arrival of the ICG bolus. The average accumulated intensity is then computed by multiplying initial frame values by the number of frames in the sequence.

- 5
- Alternatively, in the absence of a separate “0 Marker”, a value for the “0 Marker” can be derived by first automatically determining what pixels represent tissue and then examining the first frame to compute the average background intensity only for those tissue pixels. The changing pixels are those which receive blood with ICG. To locate these tissue pixels, the software locates pixels whose intensity changes to exceed a predetermined threshold value. Unchanged pixels are disregarded.
- 10
- A physical reference standard or patch with a known near-infrared reflectance may be placed in the field of view. Several of these physical patches would be provided to simulate different skin tones with known reflectance in the visual spectrum. The “0 Marker” could then be explicitly placed over these markers to approximate the accumulated intensity underneath the tissue that is not perfused with ICG-laden blood. This would allow normalization to different illumination conditions in the operating room.
- 15
- [0044]** In summary, labels can be used to easily compare different perfusion boundaries to the perfusion that is present in known good tissue. These labels now correct for the effects of residual ICG, camera noise, and other NIR scattering effects.
- 20
- [0045]** The described embodiments detect a fluorescence signal emitted transcutaneously by ICG following excitation in the near-infrared spectral range. However, those of skill in the art will appreciate that other dyes which can be excited and emit fluorescence in a spectral range where tissue transmits light can also be used.
- 25
- [0046]** While the present invention has been described with reference to an example of arterial blood flow, i.e. supply of blood to the perforator vessel(s), the method may also detect graft failure due to venous congestion by quantifying and displaying the rate of change from peak intensity back down to the baseline. This will highlight venous return in the perfusion area.
- 30
- [0047]** While the invention is receptive to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be
- 35

understood, however, that the invention is not limited to the particular forms or methods disclosed, but to the contrary, the invention is meant to cover all modifications, equivalents, and alternatives falling with the spirit and scope of the appended claims.

Claims

We claim:

1. A method for evaluating perfusion of perforator vessels, comprising the steps of:
 - detecting a fluorescence response from tissue following application of a bolus of ICG into the bloodstream,
 - acquiring a temporal sequence of images of the fluorescence response over a predetermined time,
 - processing the sequence of images to yield a time-integrated intensity or time-derivative of the intensity for pixel values in the images, and
 - displaying the time-integrated intensity or time-derivative of the intensity as a color or black-and-white image.
2. The method of claim 1, wherein the sequence of images is processed by dividing the time-integrated intensity values for each pixel by an elapsed time after ICG bolus injection.
3. The method of claim 1, wherein the sequence of images is processed by determining an elapsed time after ICG bolus injection until the time-integrated fluorescence intensity for each pixel reaches a peak value.
4. The method of claim 1, wherein the sequence of images are processed by determining a peak value of the fluorescence intensity for each pixel.
5. The method of claim 1, further comprising applying a contrast transfer function to the time-integrated intensity or time-derivative of the intensity.
6. The method of claim 5, wherein the contrast transfer function represents a linear or nonlinear function which transforms the time-integrated intensity or time-derivative of the intensity into an overlay image representing different perfusion characteristics in different colors.

7. The method of claim 5, wherein the contrast transfer function is a non-linear function with regions of different slope, and wherein the different slopes and transition between the different slopes are adjusted during a procedure to evaluate the perfusion of the vessels.
8. The method of claim 6, further comprising displaying in the overlay image a zero ("0") marker representative of a background intensity of substantially unperfused tissue and a hundred ("100") marker representative of an intensity of well perfused tissue.
9. The method of claim 8, wherein the zero marker is associated with a non-fluorescent object placed on the substantially unperfused tissue.
10. The method of claim 8, wherein the zero marker is derived from a fluorescence response from tissue prior to arrival of the ICG bolus in the tissue.
11. The method of claim 7, further comprising displaying numerical values of the time-integrated intensity or time-derivative of the intensity in the overlay image.
12. The method of claim 8, further comprising the steps of:
 - normalizing the time-integrated intensity or the or time-derivative of the intensity to a range between the zero marker and the hundred marker, and
 - displaying normalized numerical values of the time-integrated intensity or the or time-derivative of the intensity in the overlay image.
13. The method of claim 8, wherein the normalized numerical values of the time-integrated intensity ratio or the time-derivative of the intensity are computed for different image regions of an anatomical feature.
14. The method of claim 9, wherein the normalized numerical values of the time-integrated intensity ratio or of the time-derivative of the intensity are computed with the following steps:
 - computing the time-integrated intensity or the time-derivative of the intensity for all pixels,

averaging the time-integrated intensity or the time-derivative of the intensity over a predefined region in the image,

normalizing the averaged time-integrated intensity or the time-derivative of the intensity to a maximum value of the time-integrated intensity or of the time-derivative of the intensity in the entire image, and

scaling the normalized averaged time-integrated intensity or the time-derivative of the intensity with the maximum value of the contrast transfer function.

15. A method for evaluating perfusion of perforator vessels, comprising the steps of:

detecting a fluorescence response from tissue following application of a bolus of ICG into the bloodstream;

acquiring a temporal sequence of images of the fluorescence response over a predetermined time;

processing the sequence of images to yield a time-integrated intensity or time-derivative of the intensity for pixel values in the images;

identifying a first reference label associated with native tissue apart from a flap of the perforator vessel and a second reference label associated with tissue achieving a predetermined perfusion;

normalizing at least one additional label to the range established by the first and second reference labels; and

displaying the time-integrated intensity or time-derivative of the intensity as a color or black-and-white image, and displaying the first reference label, the second reference label, and the at least one additional label on the image.

16. An apparatus for evaluating perfusion of perforator vessels, comprising:
- means for detecting a fluorescence response from tissue following application of a bolus of ICG into the bloodstream,
 - means for acquiring a temporal sequence of images of the fluorescence response over a predetermined time,
 - means for processing the sequence of images to yield a time-integrated intensity or time-derivative of the intensity for pixel values in the images, and
 - means for displaying the time-integrated intensity or time-derivative of the intensity as a color or black-and-white image.




FIG. 1




FIG. 2




FIG. 3



FIG. 4




FIG. 5




FIG. 6

7/10





FIG. 7

SUBSTITUTE SHEET (RULE 26)

8/10





FIG. 8

SUBSTITUTE SHEET (RULE 26)





FIG. 9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2011/002381

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC: A61B 6/00 (2006.01) , A61B 5/00 (2006.01) , A61B 6/03 (2006.01) According to International Patent Classification (IPC) or to both national classification and IPC</p>																										
<p>B. FIELDS SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols) IPC (2006): A61B (in combination with keywords)</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p> <p>Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) Database: TotalPatent, Canadian Patent Database (Intellect), EPOQUE (EPODOC), USPTO West, IEEE Xplore Keywords: angiography, perfusion, fluorescence, image processing, vessel, vein, perforator, indocyanine, ICG</p>																										
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:10%;">Category*</th> <th style="width:60%;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="width:30%;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X --- Y</td> <td>US 2008/0071176 (DOCHERTY et al.) 20 March 2008 (20-03-2008) * Abstract, paragraphs [0012]-[0014], [0016], [0017], [0053], [0056] and [0059]-[0062] *</td> <td>1-11 and 16 --- 12-15</td> </tr> <tr> <td>X --- Y</td> <td>WO 2004/052195 (KELTY) 24 June 2004 (24-06-2004) * page 12, lines 7-23; page 8, lines 23-26; page 8, line 28 to page 9, line 6; page 10, line 12 to page 11, line 18; page 12, lines 7-34 *</td> <td>1-11 and 16 --- 12-15</td> </tr> <tr> <td>Y</td> <td>WO 2009/092162 (DVORSKY et al.) 30 July 2009 (30-07-2009) * page 10, line 20 to page 12, line 18 *</td> <td>12-15</td> </tr> <tr> <td>X, P</td> <td>WO 2009/127972 (DVORSKY et al.) 22 October 2009 (22-10-2009)</td> <td>1-16</td> </tr> <tr> <td>A</td> <td>US 2002/0099279 (PFEIFFER et al.) 25 July 2002 (25-07-2002)</td> <td>1-16</td> </tr> <tr> <td>A</td> <td>US 2006/0147897 (GRINVALD et al.) 06 July 2006 (06-07-2006)</td> <td>1-16</td> </tr> <tr> <td>A</td> <td>US 2003/0064025 (YANG et al.) 03 April 2003 (03-04-2003)</td> <td>1-16</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X --- Y	US 2008/0071176 (DOCHERTY et al.) 20 March 2008 (20-03-2008) * Abstract, paragraphs [0012]-[0014], [0016], [0017], [0053], [0056] and [0059]-[0062] *	1-11 and 16 --- 12-15	X --- Y	WO 2004/052195 (KELTY) 24 June 2004 (24-06-2004) * page 12, lines 7-23; page 8, lines 23-26; page 8, line 28 to page 9, line 6; page 10, line 12 to page 11, line 18; page 12, lines 7-34 *	1-11 and 16 --- 12-15	Y	WO 2009/092162 (DVORSKY et al.) 30 July 2009 (30-07-2009) * page 10, line 20 to page 12, line 18 *	12-15	X, P	WO 2009/127972 (DVORSKY et al.) 22 October 2009 (22-10-2009)	1-16	A	US 2002/0099279 (PFEIFFER et al.) 25 July 2002 (25-07-2002)	1-16	A	US 2006/0147897 (GRINVALD et al.) 06 July 2006 (06-07-2006)	1-16	A	US 2003/0064025 (YANG et al.) 03 April 2003 (03-04-2003)	1-16
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																								
X --- Y	US 2008/0071176 (DOCHERTY et al.) 20 March 2008 (20-03-2008) * Abstract, paragraphs [0012]-[0014], [0016], [0017], [0053], [0056] and [0059]-[0062] *	1-11 and 16 --- 12-15																								
X --- Y	WO 2004/052195 (KELTY) 24 June 2004 (24-06-2004) * page 12, lines 7-23; page 8, lines 23-26; page 8, line 28 to page 9, line 6; page 10, line 12 to page 11, line 18; page 12, lines 7-34 *	1-11 and 16 --- 12-15																								
Y	WO 2009/092162 (DVORSKY et al.) 30 July 2009 (30-07-2009) * page 10, line 20 to page 12, line 18 *	12-15																								
X, P	WO 2009/127972 (DVORSKY et al.) 22 October 2009 (22-10-2009)	1-16																								
A	US 2002/0099279 (PFEIFFER et al.) 25 July 2002 (25-07-2002)	1-16																								
A	US 2006/0147897 (GRINVALD et al.) 06 July 2006 (06-07-2006)	1-16																								
A	US 2003/0064025 (YANG et al.) 03 April 2003 (03-04-2003)	1-16																								
<p><input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tbody> <tr> <td style="width:50%;"> * Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width:50%;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </tbody> </table>			* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family																						
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family																									
Date of the actual completion of the international search 25 January 2012 (25-01-2012)		Date of mailing of the international search report 1 February 2012 (01-02-2012)																								
Name and mailing address of the ISA/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001-819-953-2476		Authorized officer Alan Chan (819) 934-7888																								

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/IB2011/002381

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6621917 (VILSER) 16 September 2003 (16-09-2003)	1-16

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IB2011/002381

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date		
US2008071176A1	20 March 2008 (20-03-2008)	AT375749T	15 November 2007 (15-11-2007)		
		AT506005T	15 May 2011 (15-05-2011)		
		AU782257B2	14 July 2005 (14-07-2005)		
		AU6767500A	30 April 2001 (30-04-2001)		
		BR0014289A	02 July 2002 (02-07-2002)		
		CA2339214A1	24 March 2001 (24-03-2001)		
		CN1399528A	26 February 2003 (26-02-2003)		
		CN101264014A	17 September 2008 (17-09-2008)		
		CN101264014B	25 August 2010 (25-08-2010)		
		CN101406392A	15 April 2009 (15-04-2009)		
		CN101406392B	18 May 2011 (18-05-2011)		
		DE60036781D1	29 November 2007 (29-11-2007)		
		DE60036781T2	24 July 2008 (24-07-2008)		
		DE60045880D1	01 June 2011 (01-06-2011)		
		DK1143852T3	26 November 2007 (26-11-2007)		
		EP1143852A1	17 October 2001 (17-10-2001)		
		EP1143852A4	18 August 2004 (18-08-2004)		
		EP1143852B1	17 October 2007 (17-10-2007)		
		EP1849408A2	31 October 2007 (31-10-2007)		
		EP1849408A3	07 November 2007 (07-11-2007)		
		EP1852061A1	07 November 2007 (07-11-2007)		
		EP1852063A1	07 November 2007 (07-11-2007)		
		EP1852063B1	20 April 2011 (20-04-2011)		
		EP2281503A2	09 February 2011 (09-02-2011)		
		EP2281503A3	29 June 2011 (29-06-2011)		
		ES2292463T3	16 March 2008 (16-03-2008)		
		HK1040897A1	15 February 2008 (15-02-2008)		
		JP2003510121A	18 March 2003 (18-03-2003)		
		JP3881550B2	14 February 2007 (14-02-2007)		
		JP2006192280A	27 July 2006 (27-07-2006)		
		JP2011147797A	04 August 2011 (04-08-2011)		
		MXPA02003064A	20 August 2003 (20-08-2003)		
		PT1143852E	08 November 2007 (08-11-2007)		
		US6915154B1	05 July 2005 (05-07-2005)		
		US7881777B2	01 February 2011 (01-02-2011)		
		US2005182434A1	18 August 2005 (18-08-2005)		
		WO0122870A1	05 April 2001 (05-04-2001)		
		WO2004052195A1	24 June 2004 (24-06-2004)	AU2003300575A1	30 June 2004 (30-06-2004)
				DE10257743A1	29 July 2004 (29-07-2004)
				DE10257743B4	23 November 2006 (23-11-2006)
WO2009092162A1	30 July 2009 (30-07-2009)	CA2750760A1	30 July 2010 (30-07-2010)		
		CN102083362A	01 June 2011 (01-06-2011)		
		EP2249703A1	17 November 2010 (17-11-2010)		
		EP2268201A2	05 January 2011 (05-01-2011)		
		JP2011509768A	31 March 2011 (31-03-2011)		
		JP2011519589A	14 July 2011 (14-07-2011)		
		KR20100136540A	28 December 2010 (28-12-2010)		
		US2010305454A1	02 December 2010 (02-12-2010)		
		US2011306877A1	15 December 2011 (15-12-2011)		
		WO2009127972A2	22 October 2009 (22-10-2009)		
		WO2009127972A3	28 January 2010 (28-01-2010)		

Continued in Supplemental Box

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2011/002381

Continuation of patent family members:

WO2009127972A2	22 October 2009 (22-10-2009)	CA2750760A1 CN102083362A EP2249703A1 EP2268201A2 JP2011509768A JP2011519589A KR20100136540A US2010305454A1 US2011306877A1 WO2009092162A1 WO2009127972A3	30 July 2010 (30-07-2010) 01 June 2011 (01-06-2011) 17 November 2010 (17-11-2010) 05 January 2011 (05-01-2011) 31 March 2011 (31-03-2011) 14 July 2011 (14-07-2011) 28 December 2010 (28-12-2010) 02 December 2010 (02-12-2010) 15 December 2011 (15-12-2011) 30 July 2009 (30-07-2009) 28 January 2010 (28-01-2010)
US2002099279A1	25 July 2002 (25-07-2002)	AT328535T CA2363770A1 CA2363770C DE10059070C1 EP1210906A1 EP1210906B1 ES2266073T3 JP2002219129A US6631286B2	15 June 2006 (15-06-2006) 28 May 2002 (28-05-2002) 21 June 2005 (21-06-2005) 14 February 2002 (14-02-2002) 05 June 2002 (05-06-2002) 07 June 2006 (07-06-2006) 01 March 2007 (01-03-2007) 06 August 2002 (06-08-2002) 07 October 2003 (07-10-2003)
US2006147897A1	06 July 2006 (06-07-2006)	AU2003302577A1 AU2003302577A8 CN1744853A CN1744853B EP1592336A2 EP1592336A4 JP2006519032A WO2004049899A2 WO2004049899A3	23 June 2004 (23-06-2004) 23 June 2004 (23-06-2004) 08 March 2006 (08-03-2006) 12 May 2010 (12-05-2010) 09 November 2005 (09-11-2005) 12 August 2009 (12-08-2009) 24 August 2006 (24-08-2006) 17 June 2004 (17-06-2004) 15 September 2005 (15-09-2005)
US2003064025A1	03 April 2003 (03-04-2003)	AU2002305148A1 WO02080756A2 WO02080756A3	21 October 2002 (21-10-2002) 17 October 2002 (17-10-2002) 31 December 2003 (31-12-2003)
US6621917B1	16 September 2003 (16-09-2003)	DE19648935A1 DE19648935B4 EP1065966A1 JP2000504256A JP4140738B2 WO9823202A1	28 May 1998 (28-05-1998) 15 May 2008 (15-05-2008) 10 January 2001 (10-01-2001) 11 April 2000 (11-04-2000) 27 August 2008 (27-08-2008) 04 June 1998 (04-06-1998)

专利名称(译)	定位和分析穿孔器皮瓣，用于整形和重建手术		
公开(公告)号	EP2618737A1	公开(公告)日	2013-07-31
申请号	EP2011826475	申请日	2011-09-20
[标]申请(专利权)人(译)	诺瓦达克技术公司		
申请(专利权)人(译)	NOVADAQ科技股份有限公司.		
当前申请(专利权)人(译)	NOVADAQ科技股份有限公司.		
[标]发明人	DVORSKY PETER GOYETTE DAVID MARK HENRI		
发明人	DVORSKY, PETER GOYETTE, DAVID, MARK, HENRI		
IPC分类号	A61B6/00 A61B5/00 A61B6/03		
CPC分类号	A61B5/0059 A61B5/413 A61B5/489 A61B2017/00792		
代理机构(译)	严实， CORNELIS MARINUS		
优先权	12/933477 2010-09-20 US		
其他公开文献	EP2618737B1 EP2618737A4		
外部链接	Espacenet		

摘要(译)

公开了一种使用ICG荧光血管造影成像术前识别用于塑料和/或重建手术的穿支血管的方法和装置。时间分辨图像处理用于突出穿孔器位置并且通过各种计算的度量在候选穿孔器之间实现视觉区分。基于这些度量，外科医生能够交互地定位和选择适合于整形和重建手术的穿孔器血管。